Skip to main content

Advertisement

SpringerLink
Log in

A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer

  • Letter to the editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59

    Article  CAS  PubMed  Google Scholar 

  2. Rahman N, Scott RH (2007) Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 16(Spec No 1):R60–R66

    Article  CAS  PubMed  Google Scholar 

  3. Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093

    Article  CAS  PubMed  Google Scholar 

  4. Quaye L, Tyrer J, Ramus SJ et al (2009) Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS One 4:e5983

    Article  PubMed  Google Scholar 

  5. Bell DW, Varley JM, Szydlo TE et al (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531

    Article  CAS  PubMed  Google Scholar 

  6. Wu X, Webster SR, Chen J (2001) Characterization of tumor-associated Chk2 mutations. J Biol Chem 276:2971–2974

    Article  CAS  PubMed  Google Scholar 

  7. Shaag A, Walsh T, Renbaum P et al (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14:555–563

    Article  CAS  PubMed  Google Scholar 

  8. Dong X, Wang L, Taniguchi K et al (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270–280

    Article  CAS  PubMed  Google Scholar 

  9. Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388

    Article  CAS  PubMed  Google Scholar 

  10. Anonymous (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 74:1175–1182

    Article  Google Scholar 

  11. Wasielewski M, den Bakker MA, van den Ouweland A et al (2009) CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 116:397–400

    Article  CAS  PubMed  Google Scholar 

  12. Weischer M, Bojesen SE, Ellervik C et al (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 26:542–548

    Article  PubMed  Google Scholar 

  13. Millevoi S, Bernat S, Telly D et al (2009) The c.5242C > A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat. doi:10.1007/s10549-009-0392-3

  14. Oldenburg RA, Kroeze-Jansema K, Kraan J et al (2003) The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 63:8153–8157

    CAS  PubMed  Google Scholar 

  15. Rashid MU, Jakubowska A, Justenhoven C et al (2005) German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 41:2896–2903

    Article  CAS  PubMed  Google Scholar 

  16. Martinez-Bouzas C, Beristain E, Guerra I et al (2007) CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat 103:111–113

    Article  PubMed  Google Scholar 

  17. Osorio A, Rodriguez-Lopez R, Diez O et al (2004) The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 108:54–56

    Article  CAS  PubMed  Google Scholar 

  18. Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110:161–167

    Article  CAS  PubMed  Google Scholar 

  19. Bieche I, Lerebours F, Tozlu S et al (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10:6789–6795

    Article  CAS  PubMed  Google Scholar 

  20. Lerebours F, Vacher S, Andrieu C et al (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8:41

    Article  PubMed  Google Scholar 

  21. Van Laere S, Van der Auwera I, Van den Eynden GG et al (2005) Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93:237–246

    Article  CAS  PubMed  Google Scholar 

  22. Williams LH, Choong D, Johnson SA et al (2006) Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 12:6967–6972

    Article  CAS  PubMed  Google Scholar 

  23. Antoni L, Sodha N, Collins I et al (2007) CHK2 kinase: cancer susceptibility and cancer therapy—two sides of the same coin? Nat Rev Cancer 7:925–936

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Groupe de Recherche de l’Institut Claudius Regaud. The authors want to thank Dr Maria-Isabel Tejada (Lisboa, Portugal) for providing us a c.1100DelC DNA control, Isabelle Gitlaw, Pauline Dejean and Chantal Darnau for their efficient technical assistance.

Author information

Authors and Affiliations

  1. Laboratoire d’Oncogénétique, Institut Claudius Regaud, Toulouse, 31000, France

    Pauline Escudie, Sylvia Monteil-Onteniente, Gilles Favre & Christine Toulas

  2. Département d’Oncologie Médicale, Institut Claudius Regaud, Toulouse, 31000, France

    Laurence Gladieff, Viviane Feillel & Rosine Guimbaud

  3. CHU Toulouse, Pôle Digestif, Toulouse, 31000, France

    Rosine Guimbaud

  4. Université Toulouse III Paul Sabatier, UPS, Toulouse, 31062, France

    Rosine Guimbaud & Gilles Favre

  5. INSERM, U563, Toulouse, Centre de Physiopathologie de Toulouse Purpan, Toulouse, 31300, France

    Rosine Guimbaud, Gilles Favre & Christine Toulas

  6. Institut Claudius Regaud, INSERMU563, 20-24 rue du Pont St-Pierre, 31052, Toulouse, France

    Christine Toulas

Authors
  1. Pauline Escudie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvia Monteil-Onteniente
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Gladieff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viviane Feillel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosine Guimbaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gilles Favre
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine Toulas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Toulas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escudie, P., Monteil-Onteniente, S., Gladieff, L. et al. A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer. Breast Cancer Res Treat 120, 267–270 (2010). https://doi.org/10.1007/s10549-009-0551-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0551-6

Keywords

Search

Navigation